Not going to be boring, cell-based cancer immunotherapies.
There have been JUNO-related posts accumulating in other threads. A search will find them. Figured it was time for a devoted thread. Today's story? The Editas deal is supposed to reveal JUNO weakness relative to Cellectis (CLLS), that "allogeneic" has a competitive advantage.
That's today's story. A giant land-grab, deals between innovators flying amok, with a focus on IP that will surface in about three years. It's like 1995, all over again. Heavenly. |
